Part 3: Rare Disease Clinical Development – Strategies for Ensuring Endpoint Integrity

Life Sciences, Clinical Trials,
  • Tuesday, April 21, 2020

Because clinical trial endpoints for rare diseases are often not well defined, consistency of endpoint assessments across study sites and over time are critical to ensuring data integrity. Having a cohesive training strategy that includes conducting pre-study evaluation and training, as well as ongoing review of clinical evaluator (CE) performance and adherence to standardised procedures is an important contributor to success.

In this free webinar, Medpace partners with Michelle Eagle of ATOM International, a provider of CE training for clinical trials across the world, to discuss approaches and steps that can be taken to ensure quality and integrity. For example, neuromuscular studies incorporate training of clinical evaluators at investigator meetings, support video-recording of patient assessments at study visits to review for quality control and perform periodic refresher training throughout the course of a study.

Topics will include:

  • What does a comprehensive training program look like?
  • How natural history data can inform endpoint selection (real-word examples)
  • Rating assessment considerations and review (video QC and clinical assessment reliability)
  • The role of data management – cleaning and coding of data to create structured output for review and reliability

To register for the other parts in this webinar series, please click below:

Speakers

Meredith James, Master Physiotherapist, ATOM International

Meredith James is a neuromuscular physiotherapist by training and a senior member of the ATOM International team. Working as part of a team of international trainers in the development, implementation and quality control of standardised endpoint study assessments, she trains Clinical Evaluators across the globe, leads Investigator meeting training, and works with pharmaceutical companies on protocol development and endpoint selection and analysis.

Message Presenter
http://Chad%20Leslie,%20Medpace

Chad Leslie, Sr. Data Manager, Medpace

Chad Leslie is a Senior Data Manager with 12+ years of industry experience in data collection for drug development. Mr. Leslie specializes in EDC builds/endpoint data management of phase 1-3 oncology and rare disease studies. These studies include investigational products for Duchenne muscular dystrophy, Charcot-Marie-Tooth disease, Facioscapulohumeral Muscular Dystrophy, immunotherapy, targeted agents, viral vector, novel biologic agents, and radioactive agents. He holds an undergraduate degree in mathematics from the University of Cincinnati.

Message Presenter
http://Michelle%20Petersen,%20Medpace

Michelle Petersen, MS, Senior Director, Clinical Trial Management, Medpace

Michelle Petersen has 13 years’ experience in preclinical and clinical research which includes managing global studies in multiple phases of clinical development. She has managed multiple global rare/ultra-rare disease trials with a focus on neuromuscular and pediatric disorders. Ms. Petersen is a member of Medpace’s specialized Rare Disease Consortium and she is adept in developing strategies necessary to address the potential challenges of recruitment and logistical requirements for studies of this nature. Ms. Petersen holds a Master of Science degree in Physiology from the University of Cincinnati College of Medicine.

Message Presenter

Who Should Attend?

This webinar will appeal to VPs, directors, managers and department heads working within:

  • Clinical Affairs
  • Clinical Research
  • Clinical Pharmacology
  • Clinical Outsourcing
  • Project Management
  • Regulatory Affairs
  • Medical Affairs

What You Will Learn

Participants will learn about:

  • What a comprehensive training program looks like
  • How natural history data can inform endpoint selection (real-word examples)
  • Rating assessment considerations and review (video QC and clinical assessment reliability)
  • The role of data management – cleaning and coding of data to create structured output for review and reliability

Xtalks Partner

Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 3,400 people across 37 countries.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account